Skip Navigation
Toggle Navigation
About
Our Company
Executive Team
Board of Directors
Partners
Our Culture
Programs
Pipeline
Scientific Presentations
Clinical Trials
Expanded Access Policy
Investors
Overview
News & Events
Corporate Governance
Financial Information
Stock Information
IR Resources
Careers
Who We Are
Job Opportunities
Contact Us
Programs
Scientific Presentations
04.09.2024
FURVENT: Global, Phase 3 Trial Testing Firmonertinib (Furmonertinib) versus Chemotherapy as First-Line Treatment for Advanced NSCLC with EGFR Exon 20 Insertion Mutations
04.08.2024
Firmonertinib (furmonertinib) is a highly brain-penetrant EGFR inhibitor broadly active against uncommon EGFR mutations, including PACC and exon 20 insertions
04.08.2024
FURTHER (FURMO-002): Global Study to Evaluate Firmonertinib (Furmonertinib) in Patients with EGFR Mutant NSCLC Including Uncommon EGFR Mutations
09.10.2023
FAVOUR: A phase 1b study of furmonertinib, an oral, brain penetrant, selective EGFR inhibitor, in patients with advanced NSCLC with EGFR Exon 20 insertions
09.09.2022
Furmonertinib is an Oral, Irreversible, Highly Brain-Penetrant Pan-EGFR Mutant Inhibitor with Activity Against Classical and Atypical EGFR Mutations
03.08.2022
FURLONG: Furmonertinib versus gefitinib in treatment-naïve EGFR mutated non-small cell lung cancer: a randomized, double-blind, multi-center, phase III study
09.16.2021
Preclinical and Preliminary Clinical Investigations of Furmonertinib in NSCLC with EGFR exon 20 insertions (20ins)
